VANCOUVER, Wash., June 30, 2014 /PRNewswire/ — SteriWeb Medical has announced FDA over the counter clearance for Omnicide Antimicrobial Gel , a long-lasting, non-antibiotic, petrolatum based topical gel with proven effectiveness against even the most resistant, virulent bacteria, such as MRSA, VRE, and CRE. Laboratory data has also demonstrated complete effectiveness against pathogenic fungi, molds, and yeasts, rendering Omnicide an appropriate choice for a wide variety of clinical conditions and an ideal addition to any topical infection treatment protocol. Omnicide’s unique combination of antimicrobial ingredients differentiates it from topical antibiotics, which have become far less clinically effective as pathogenic bacteria, such as MRSA, have developed, and continue to develop, resistance over time. SteriWeb Founder and Chief Operating Officer Bradley Burnam states: “In light of the recent World Health Organization’s landmark report on antibiotic resistance, it is clear that currently available topical infection treatments are becoming less and less effective. Omnicide is a timely and important innovation.”

SteriWeb Medical is dedicated to protecting patients and caregivers from the human and economic costs of infection. For more information on the SteriWeb suite of wound care products, including Omnicide and the revolutionary SPD breathable barrier dressing, please visit www.steriwebrx.com.

SOURCE SteriWeb Medical, LLC